BioDelivery Sciences International Inc logo

BDSI - BioDelivery Sciences International Inc News Story

$3.18 -0.2  -5.9%

Last Trade - 10/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £227.2m
Enterprise Value £203.7m
Revenue £110.8m
Position in Universe 4065th / 6853

BioDelivery Sciences pain drug fails late-stage study

March 30 (Reuters) - Drugmaker BioDelivery Sciences 
International Inc  BDSI.O  said its drug to treat painful nerve 
damage caused by diabetes failed to meet its main goals in a 
late-stage study. 
    The topical gel was not effective against a placebo in 
treating painful diabetic neuropathy. 
 
 (Reporting By Samantha Kareen Nair; Editing by Saumyadeb 
Chakrabarty) 
 ((SamanthaKareen.Nair@thomsonreuters.com; Reuters Messaging: 
samanthakareen.nair.thomsonreuters.com@reuters.net)) 
 
Keywords: BIODELIVERY SCI STUDY/
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.